Cidara Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 69
- Market Cap
- -
- Website
- http://www.cidara.com
- Introduction
Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. Its product pipeline includes Rezafungin Acetate and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.
Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications
- Conditions
- Influenza
- Interventions
- Combination Product: CD388 InjectionCombination Product: Placebo
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Cidara Therapeutics Inc.
- Target Recruit Count
- 5000
- Registration Number
- NCT06609460
- Locations
- 🇺🇸
Clinical Site Partners, LLC dba Flourish Research, Miami, Florida, United States
🇺🇸Healthcare Clinical Data, Inc., North Miami, Florida, United States
🇺🇸Pinnacle Research Group, LLC, Anniston, Alabama, United States
Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects
- Conditions
- Healthy
- Interventions
- Combination Product: CD388 InjectionDrug: Saline placebo
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Cidara Therapeutics Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT05619536
- Locations
- 🇺🇸
Altasciences Clinical Los Angeles, Inc., Cypress, California, United States
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
- Conditions
- Influenza
- Interventions
- Drug: Saline placeboCombination Product: CD388
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Cidara Therapeutics Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT05523089
- Locations
- 🇬🇧
hVIVO Services Limited, London, United Kingdom
Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects
- Conditions
- Healthy
- Interventions
- Combination Product: CD388 InjectionDrug: Saline placebo
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Cidara Therapeutics Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT05285137
- Locations
- 🇺🇸
Altasciences Clinical Kansas, Inc., Overland Park, Kansas, United States
Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
- Conditions
- CandidemiaFungal InfectionInvasive CandidiasesMycoses
- Interventions
- Drug: oral placeboDrug: intravenous placebo
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Cidara Therapeutics Inc.
- Target Recruit Count
- 199
- Registration Number
- NCT03667690
- Locations
- 🇮🇱
Chaim Sheba Medical Center, Tel Hashomer, Israel
🇪🇸Hospital Clinic of Barcelona, Barcelona, Spain
🇮🇹University Polyclinic Foundation Agostino Gemelli - IRCCS, Rome, Italy
Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization
- Conditions
- MycosesYeast InfectionCandidiasis, VulvovaginalMoniliasis, VulvovaginalVaginitis, Monilial
- First Posted Date
- 2016-09-02
- Last Posted Date
- 2018-03-02
- Lead Sponsor
- Cidara Therapeutics Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02888197
- Locations
- 🇺🇸
The Women's Clinical, P.A., Little Rock, Arkansas, United States
🇺🇸Soffolk OB/GYN, Port Jefferson, New York, United States
🇺🇸Eastern Carolina Women's Center, New Bern, North Carolina, United States
CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension
- Conditions
- Fungal InfectionFungemiaInvasive CandidiasisCandidemiaMycoses
- Interventions
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Cidara Therapeutics Inc.
- Target Recruit Count
- 207
- Registration Number
- NCT02734862
- Locations
- 🇪🇸
University Hospital La Paz, Madrid, Spain
🇧🇪UCL Saint-LUC, Brussels, Belgium
🇺🇸Virginia Tech, Carillion School of Medicine, Roanoke, Virginia, United States
RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections
- Conditions
- Candidiasis, VulvovaginalMycosesYeast InfectionMoniliasis, VulvovaginalVaginitis, Monilial
- Interventions
- Drug: CD101 Vaginal Gel (3%)Drug: CD101 Vaginal Ointment (6%)Drug: CD101 External gel (1%)Drug: CD101 External ointment (1%)
- First Posted Date
- 2016-04-11
- Last Posted Date
- 2020-08-31
- Lead Sponsor
- Cidara Therapeutics Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT02733432
- Locations
- 🇺🇸
Women's Medical Research, Clearwater, Florida, United States
🇺🇸Augusta University, Augusta, Georgia, United States
🇺🇸Seattle Women's Health, Research, Gynecology, Seattle, Washington, United States
An Ascending Multiple Dose Study of CD101 IV in Healthy Subjects
- Conditions
- Healthy
- Interventions
- Drug: CD101 IVDrug: Placebo
- First Posted Date
- 2015-09-16
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Cidara Therapeutics Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02551549
- Locations
- 🇺🇸
Celerion Inc, Tempe, Arizona, United States
A Single Ascending Dose Study of CD101 IV in Healthy Subjects
- Conditions
- Healthy
- Interventions
- Drug: CD101 IVDrug: Placebo
- First Posted Date
- 2015-08-06
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Cidara Therapeutics Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02516904
- Locations
- 🇺🇸
Celerion Inc, Tempe, Arizona, United States